Semaglutide price depends on which product the question is about. Ozempic, Wegovy and Rybelsus are FDA-approved prescription medicines with list prices and self-pay prices that Novo Nordisk publishes. Research-grade semaglutide is something else: a lyophilized reagent sold for laboratory research use only, priced per vial and per mg. This page sets out both sets of numbers as they stood on November 17, 2026, and keeps the two categories apart.
Quick answer: As published by Novo Nordisk on November 17, 2026, Ozempic lists at $1,027.51 per pen and Wegovy at $1,349.02 per package. Novo’s self-pay prices for Wegovy pens are $349 per box of four pens after a $199 introductory offer. Research-grade semaglutide, a different product category, listed at $39.99–$109.99 per vial at US research suppliers. Vitrapep lists 15 mg at $79.99.
Two different categories, two different prices
Semaglutide is a GLP-1 analogue with two amino acid substitutions compared with human GLP-1 and a fatty acid side chain attached at lysine 26 through a linker (Lau et al., 2015). The name covers two kinds of product that should not be confused:
- Prescription medicines. Ozempic, Wegovy and Rybelsus are FDA-approved, made and tested under FDA drug manufacturing rules, and dispensed by a pharmacy on a prescription. They have list prices, insurance coverage rules and manufacturer savings programs.
- Research reagents. Research-grade semaglutide is a lyophilized powder sold for laboratory work. It has not been reviewed by FDA as a drug. It is for laboratory research use only, not for human or veterinary use.
One is not a substitute for the other, and the prices below are not a comparison between them. FDA has warned companies that sold semaglutide labeled “for research purposes” or “not for human consumption” directly to consumers, and it urges consumers not to purchase those products (FDA, 2026).
The approved semaglutide products
FDA records show three brand names and several presentations:
- Ozempic (NDA 209637) was first approved on December 5, 2017 (FDA, Drugs@FDA). Its label covers adults with type 2 diabetes (Novo Nordisk, 2026a). Ozempic tablets are now also listed under NDA 213051.
- Rybelsus (NDA 213051), a semaglutide tablet, was first approved on September 20, 2019 (FDA, Drugs@FDA).
- Wegovy (NDA 215256) was first approved on June 4, 2021, and Wegovy tablets (NDA 218316) on December 22, 2025 (FDA, Drugs@FDA; FDA, Drugs@FDA). Its label covers chronic weight management in people with obesity, or overweight with a weight-related condition, and cardiovascular risk reduction in adults with established cardiovascular disease. The pen form, not the tablets, is also approved for a form of liver disease (MASH) with moderate to advanced fibrosis (Novo Nordisk, 2026b).
Ozempic, Wegovy and Rybelsus prices as Novo publishes them
Novo defines list price as the price a manufacturer sets for a medication before any discounts or rebates are applied (NovoCare). What a person pays at the pharmacy depends on insurance and savings programs. These are the figures on Novo Nordisk’s NovoCare site on November 17, 2026:
Novo Nordisk list and self-pay prices for semaglutide medicines, as published November 17, 2026
| Product | List price | NovoCare self-pay price |
|---|---|---|
| Ozempic pen | $1,027.51 per pen | $349 per pen box; $499 for the highest-strength pen; $199 introductory offer |
| Ozempic tablets | $1,027.51 for each listed strength | From $149 per bottle of 30 tablets; varies by strength |
| Wegovy pen | $1,349.02 per package | $349 per box of four pens; $199 introductory offer |
| Wegovy HD pen | $1,349.02 per package | $399 per box |
| Wegovy tablets | $1,349.02 per package | $149, $199 or $299 per bottle of 30 tablets, by strength |
| Rybelsus | Not shown on the NovoCare page checked | Not listed on the NovoCare self-pay page |
Sources: NovoCare list-price pages for Ozempic and Wegovy; NovoCare self-pay page, all read November 17, 2026. The $199 introductory offers apply to new patients for their first two fills at the lowest strengths, through December 31, 2026. Novo states that pricing will be updated after that date. A prescription is required.
Three more points from Novo’s own pages:
- Insurance savings. NovoCare lists savings offers under which eligible commercially insured patients may pay as little as $25 per fill. For Wegovy, maximum savings are $100 per fill, where a fill is one box of four pens or one bottle of 30 tablets (NovoCare, 2026).
- Self-pay rules. Government-insured patients can use the self-pay price only by paying outside their insurance, and those payments do not count toward deductibles (NovoCare, 2026).
- A 2027 list price cut. On February 24, 2026, Novo announced that the US list price of Wegovy, Ozempic and Rybelsus will fall to $675, the same figure for every strength, effective January 1, 2027. Novo said the change does not affect self-pay prices (Novo Nordisk, 2026c).
Research-grade semaglutide prices
Research-grade semaglutide is priced like any research peptide: per vial and per mg. We checked US supplier product pages on November 17, 2026, and recorded the listed single-vial price. Prices exclude shipping, codes and pack discounts.
Research-grade semaglutide prices at US suppliers, checked November 17, 2026
| Supplier | Vial size | Listed price | Price per mg |
|---|---|---|---|
| Zeptix Labs | 5 mg | $39.99 | $8.00 |
| Zeptix Labs | 10 mg | $59.99 | $6.00 |
| Purely Peptides | 10 mg | $59.99 | $6.00 |
| Purely Peptides | 30 mg | $109.99 | $3.67 |
| PS Peptides | 10 mg | $64.99 | $6.50 |
| American Peptides (listed as AP-SEM-1, code NN9535) | 5 mg | $60.00 | $12.00 |
| Vitrapep | 15 mg | $79.99 | $5.33 |
Sources: supplier product pages listed in the references, read November 17, 2026. Price per mg is the listed price divided by the vial size. Zeptix Labs was running a buy-one-get-one offer. The American Peptides page does not use the name semaglutide, and its other sizes showed no price or were sold out. All of these products are sold for laboratory research use only.
Across the suppliers we checked, research-grade semaglutide ran from $39.99 to $109.99 per vial and from $3.67 to $12.00 per mg. As with other research peptides, larger vials cost less per mg because filling, labeling and lot testing cost about the same for any vial size.
What moves research semaglutide prices
The levers are the same ones covered in our peptide prices explainer:
- Chemistry. Semaglutide carries a non-standard amino acid (Aib) and a fatty acid side chain on a linker (Lau et al., 2015). Each modification adds synthesis and purification work.
- Purity and testing. HPLC purity and identity by mass spectrometry, ideally from an outside laboratory and tied to the lot, cost money per batch. Our guide to reading a certificate of analysis explains what each field should show.
- Naming. Some listings use a house code or a research code instead of the compound name. If neither the page nor the certificate names the compound, identity cannot be checked against the label.
- Human-use language. A research listing should carry no dosing or human-use instructions. FDA has acted against products sold that way (FDA, 2026).
What Vitrapep charges for semaglutide
Vitrapep lists semaglutide as a 15 mg lyophilized vial at $79.99, or $5.33 per mg. Store prices may still change before launch. It is a research reagent, sold for laboratory research use only and not for human or veterinary use. It is not Ozempic, Wegovy or Rybelsus, and it is not a substitute for any prescription medicine. For sourcing questions, see where to buy semaglutide, and for how it differs chemically from tirzepatide, see tirzepatide vs semaglutide.

Semaglutide
Specifications and the current lot’s test documentation for the semaglutide sold for laboratory research.
Frequently asked questions about semaglutide price
What is the list price of Ozempic and Wegovy?
On November 17, 2026, Novo Nordisk listed Ozempic at $1,027.51 per pen and Wegovy at $1,349.02 per package, for the pen, HD pen and tablets alike (NovoCare).
What does semaglutide cost without insurance?
Novo’s NovoCare self-pay prices, which require a prescription, were $349 per box of four Wegovy pens, $399 for Wegovy HD, $149 to $299 per bottle of Wegovy tablets, and $349 to $499 per Ozempic pen box, with $199 introductory offers for new patients through December 31, 2026 (NovoCare).
Will semaglutide list prices change in 2027?
Yes. Novo announced that Wegovy, Ozempic and Rybelsus will carry a US list price of $675 from January 1, 2027, the same for every strength. Novo said self-pay prices are not affected (Novo Nordisk, 2026c).
Is research-grade semaglutide the same as Ozempic?
No. Ozempic is an FDA-approved prescription medicine, manufactured and tested under drug rules and dispensed by a pharmacy. Research-grade semaglutide is a laboratory reagent that FDA has not reviewed as a drug. It is for laboratory research use only, not for human or veterinary use, and it is not a substitute for any prescription medicine.
How much does research-grade semaglutide cost per mg?
At the US research suppliers we checked on November 17, 2026, listed prices ran from $3.67 to $12.00 per mg, depending on supplier and vial size. Vitrapep lists 15 mg at $79.99, or $5.33 per mg.
What to know now
- Approved products have published list prices. Ozempic $1,027.51 per pen; Wegovy $1,349.02 per package (NovoCare, November 17, 2026).
- Self-pay is lower than list. $149 to $499 per fill through NovoCare, by prescription, with $199 introductory offers through December 31, 2026.
- List prices drop to $675 on January 1, 2027. Novo says self-pay prices do not change.
- Research-grade semaglutide is a different category. It is a laboratory reagent at $3.67 to $12.00 per mg, not for human or veterinary use.
- Vitrapep lists 15 mg at $79.99. That is $5.33 per mg, within the research supplier range.
What we’re watching
First, January 1, 2027, when Novo’s $675 list price takes effect for Wegovy, Ozempic and Rybelsus. Second, NovoCare’s self-pay prices, which Novo says will be updated after December 31, 2026. Third, FDA enforcement against GLP-1 products sold to consumers under research labels, which FDA last updated on October 1, 2026.